Brookline Capital Markets analyst Kemp Doliver initiates coverage on Candel Therapeutics Inc. (NASDAQ: CADL) with a Buy rating and a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE